JP2022520962A - 筋痙攣の予防及び治療のためのケイ素及びマグネシウムの組合せ物 - Google Patents
筋痙攣の予防及び治療のためのケイ素及びマグネシウムの組合せ物 Download PDFInfo
- Publication number
- JP2022520962A JP2022520962A JP2021547506A JP2021547506A JP2022520962A JP 2022520962 A JP2022520962 A JP 2022520962A JP 2021547506 A JP2021547506 A JP 2021547506A JP 2021547506 A JP2021547506 A JP 2021547506A JP 2022520962 A JP2022520962 A JP 2022520962A
- Authority
- JP
- Japan
- Prior art keywords
- magnesium
- silicon
- pharmaceutical composition
- compound
- muscle
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 208000007101 Muscle Cramp Diseases 0.000 title claims abstract description 105
- 239000011777 magnesium Substances 0.000 title claims abstract description 103
- 239000010703 silicon Substances 0.000 title claims abstract description 96
- 229910052710 silicon Inorganic materials 0.000 title claims abstract description 96
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 title claims abstract description 95
- 229910052749 magnesium Inorganic materials 0.000 title claims abstract description 95
- 208000005392 Spasm Diseases 0.000 title claims abstract description 86
- 238000011282 treatment Methods 0.000 title claims abstract description 42
- 230000002265 prevention Effects 0.000 title claims abstract description 21
- 239000008194 pharmaceutical composition Substances 0.000 claims abstract description 39
- 210000002027 skeletal muscle Anatomy 0.000 claims abstract description 25
- 230000001629 suppression Effects 0.000 claims abstract description 17
- 150000002681 magnesium compounds Chemical class 0.000 claims abstract description 14
- XUIMIQQOPSSXEZ-UHFFFAOYSA-N Silicon Chemical compound [Si] XUIMIQQOPSSXEZ-UHFFFAOYSA-N 0.000 claims description 95
- 239000003381 stabilizer Substances 0.000 claims description 32
- 150000003377 silicon compounds Chemical class 0.000 claims description 28
- RMAQACBXLXPBSY-UHFFFAOYSA-N silicic acid Chemical compound O[Si](O)(O)O RMAQACBXLXPBSY-UHFFFAOYSA-N 0.000 claims description 27
- 229960001231 choline Drugs 0.000 claims description 24
- OEYIOHPDSNJKLS-UHFFFAOYSA-N choline Chemical group C[N+](C)(C)CCO OEYIOHPDSNJKLS-UHFFFAOYSA-N 0.000 claims description 19
- 239000008187 granular material Substances 0.000 claims description 18
- -1 polyphenol compound Chemical class 0.000 claims description 18
- 229920002472 Starch Polymers 0.000 claims description 15
- 230000000306 recurrent effect Effects 0.000 claims description 15
- 235000019698 starch Nutrition 0.000 claims description 15
- 239000008107 starch Substances 0.000 claims description 13
- 210000002460 smooth muscle Anatomy 0.000 claims description 11
- 239000007787 solid Substances 0.000 claims description 9
- 159000000003 magnesium salts Chemical class 0.000 claims description 7
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 7
- 150000003856 quaternary ammonium compounds Chemical class 0.000 claims description 6
- 239000011230 binding agent Substances 0.000 claims description 5
- 239000000463 material Substances 0.000 claims description 5
- 238000006116 polymerization reaction Methods 0.000 claims description 5
- 230000002496 gastric effect Effects 0.000 claims description 4
- 125000000217 alkyl group Chemical group 0.000 claims description 3
- 239000008247 solid mixture Substances 0.000 claims description 3
- ISWSIDIOOBJBQZ-UHFFFAOYSA-N Phenol Chemical compound OC1=CC=CC=C1 ISWSIDIOOBJBQZ-UHFFFAOYSA-N 0.000 claims description 2
- 125000003342 alkenyl group Chemical group 0.000 claims description 2
- 125000003545 alkoxy group Chemical group 0.000 claims description 2
- 150000001413 amino acids Chemical class 0.000 claims description 2
- 150000007524 organic acids Chemical class 0.000 claims description 2
- 235000013824 polyphenols Nutrition 0.000 claims description 2
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 claims description 2
- 108090000765 processed proteins & peptides Proteins 0.000 claims description 2
- 239000003531 protein hydrolysate Substances 0.000 claims description 2
- 229920002774 Maltodextrin Polymers 0.000 claims 1
- 239000005913 Maltodextrin Substances 0.000 claims 1
- 150000001299 aldehydes Chemical class 0.000 claims 1
- 230000000968 intestinal effect Effects 0.000 claims 1
- 229940035034 maltodextrin Drugs 0.000 claims 1
- 150000005846 sugar alcohols Polymers 0.000 claims 1
- 239000003232 water-soluble binding agent Substances 0.000 claims 1
- 239000000203 mixture Substances 0.000 abstract description 33
- 229940091250 magnesium supplement Drugs 0.000 description 88
- 238000009472 formulation Methods 0.000 description 23
- 206010010904 Convulsion Diseases 0.000 description 19
- 235000012239 silicon dioxide Nutrition 0.000 description 14
- 239000003814 drug Substances 0.000 description 13
- 239000002245 particle Substances 0.000 description 13
- LOUPRKONTZGTKE-WZBLMQSHSA-N Quinine Chemical compound C([C@H]([C@H](C1)C=C)C2)C[N@@]1[C@@H]2[C@H](O)C1=CC=NC2=CC=C(OC)C=C21 LOUPRKONTZGTKE-WZBLMQSHSA-N 0.000 description 11
- 238000000034 method Methods 0.000 description 11
- 210000003205 muscle Anatomy 0.000 description 11
- 230000036461 convulsion Effects 0.000 description 10
- 230000000694 effects Effects 0.000 description 9
- 229940079593 drug Drugs 0.000 description 8
- 238000005469 granulation Methods 0.000 description 8
- 230000003179 granulation Effects 0.000 description 8
- 239000000178 monomer Substances 0.000 description 8
- 239000002775 capsule Substances 0.000 description 7
- IJKVHSBPTUYDLN-UHFFFAOYSA-N dihydroxy(oxo)silane Chemical compound O[Si](O)=O IJKVHSBPTUYDLN-UHFFFAOYSA-N 0.000 description 7
- 150000003839 salts Chemical class 0.000 description 7
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 6
- 230000009102 absorption Effects 0.000 description 6
- 238000010521 absorption reaction Methods 0.000 description 6
- 238000009826 distribution Methods 0.000 description 6
- 210000002683 foot Anatomy 0.000 description 6
- 229960005336 magnesium citrate Drugs 0.000 description 6
- 239000004337 magnesium citrate Substances 0.000 description 6
- 235000002538 magnesium citrate Nutrition 0.000 description 6
- 208000019116 sleep disease Diseases 0.000 description 6
- PLSARIKBYIPYPF-UHFFFAOYSA-H trimagnesium dicitrate Chemical compound [Mg+2].[Mg+2].[Mg+2].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O.[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O PLSARIKBYIPYPF-UHFFFAOYSA-H 0.000 description 6
- 235000001258 Cinchona calisaya Nutrition 0.000 description 5
- 239000012876 carrier material Substances 0.000 description 5
- LOUPRKONTZGTKE-UHFFFAOYSA-N cinchonine Natural products C1C(C(C2)C=C)CCN2C1C(O)C1=CC=NC2=CC=C(OC)C=C21 LOUPRKONTZGTKE-UHFFFAOYSA-N 0.000 description 5
- 239000007788 liquid Substances 0.000 description 5
- 229960000948 quinine Drugs 0.000 description 5
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 4
- CSNNHWWHGAXBCP-UHFFFAOYSA-L Magnesium sulfate Chemical compound [Mg+2].[O-][S+2]([O-])([O-])[O-] CSNNHWWHGAXBCP-UHFFFAOYSA-L 0.000 description 4
- 241001465754 Metazoa Species 0.000 description 4
- 229920000881 Modified starch Polymers 0.000 description 4
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 4
- OIPILFWXSMYKGL-UHFFFAOYSA-N acetylcholine Chemical compound CC(=O)OCC[N+](C)(C)C OIPILFWXSMYKGL-UHFFFAOYSA-N 0.000 description 4
- 230000009471 action Effects 0.000 description 4
- 239000012159 carrier gas Substances 0.000 description 4
- 238000000576 coating method Methods 0.000 description 4
- 150000001875 compounds Chemical class 0.000 description 4
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 4
- 235000013305 food Nutrition 0.000 description 4
- 238000009140 magnesium supplementation Methods 0.000 description 4
- 235000019426 modified starch Nutrition 0.000 description 4
- 239000000902 placebo Substances 0.000 description 4
- 229940068196 placebo Drugs 0.000 description 4
- 238000002360 preparation method Methods 0.000 description 4
- 150000003248 quinolines Chemical group 0.000 description 4
- 239000007921 spray Substances 0.000 description 4
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 3
- 241000282412 Homo Species 0.000 description 3
- 239000004368 Modified starch Substances 0.000 description 3
- 229960004373 acetylcholine Drugs 0.000 description 3
- 239000002253 acid Substances 0.000 description 3
- 239000004480 active ingredient Substances 0.000 description 3
- 230000008859 change Effects 0.000 description 3
- 230000008602 contraction Effects 0.000 description 3
- 238000011161 development Methods 0.000 description 3
- 230000018109 developmental process Effects 0.000 description 3
- 239000000539 dimer Substances 0.000 description 3
- 210000003414 extremity Anatomy 0.000 description 3
- 210000001035 gastrointestinal tract Anatomy 0.000 description 3
- 238000010348 incorporation Methods 0.000 description 3
- 230000005764 inhibitory process Effects 0.000 description 3
- 238000007918 intramuscular administration Methods 0.000 description 3
- 238000001990 intravenous administration Methods 0.000 description 3
- 239000012669 liquid formulation Substances 0.000 description 3
- JFQQIWNDAXACSR-UHFFFAOYSA-L magnesium malate Chemical compound [Mg+2].[O-]C(=O)C(O)CC([O-])=O JFQQIWNDAXACSR-UHFFFAOYSA-L 0.000 description 3
- 229940096424 magnesium malate Drugs 0.000 description 3
- 230000004118 muscle contraction Effects 0.000 description 3
- 210000005036 nerve Anatomy 0.000 description 3
- 230000008569 process Effects 0.000 description 3
- 238000012552 review Methods 0.000 description 3
- 239000003826 tablet Substances 0.000 description 3
- XOAAWQZATWQOTB-UHFFFAOYSA-N taurine Chemical compound NCCS(O)(=O)=O XOAAWQZATWQOTB-UHFFFAOYSA-N 0.000 description 3
- 239000013638 trimer Substances 0.000 description 3
- 235000013343 vitamin Nutrition 0.000 description 3
- 239000011782 vitamin Substances 0.000 description 3
- 229930003231 vitamin Natural products 0.000 description 3
- 229940088594 vitamin Drugs 0.000 description 3
- HMBHAQMOBKLWRX-UHFFFAOYSA-N 2,3-dihydro-1,4-benzodioxine-3-carboxylic acid Chemical compound C1=CC=C2OC(C(=O)O)COC2=C1 HMBHAQMOBKLWRX-UHFFFAOYSA-N 0.000 description 2
- 239000001763 2-hydroxyethyl(trimethyl)azanium Substances 0.000 description 2
- QWJSAWXRUVVRLH-LREBCSMRSA-M 2-hydroxyethyl(trimethyl)azanium;(2r,3r)-2,3,4-trihydroxy-4-oxobutanoate Chemical compound C[N+](C)(C)CCO.OC(=O)[C@H](O)[C@@H](O)C([O-])=O QWJSAWXRUVVRLH-LREBCSMRSA-M 0.000 description 2
- KWIUHFFTVRNATP-UHFFFAOYSA-N Betaine Natural products C[N+](C)(C)CC([O-])=O KWIUHFFTVRNATP-UHFFFAOYSA-N 0.000 description 2
- 235000019743 Choline chloride Nutrition 0.000 description 2
- UGJMXCAKCUNAIE-UHFFFAOYSA-N Gabapentin Chemical compound OC(=O)CC1(CN)CCCCC1 UGJMXCAKCUNAIE-UHFFFAOYSA-N 0.000 description 2
- 206010020853 Hypertonic bladder Diseases 0.000 description 2
- TWRXJAOTZQYOKJ-UHFFFAOYSA-L Magnesium chloride Chemical compound [Mg+2].[Cl-].[Cl-] TWRXJAOTZQYOKJ-UHFFFAOYSA-L 0.000 description 2
- KWIUHFFTVRNATP-UHFFFAOYSA-O N,N,N-trimethylglycinium Chemical compound C[N+](C)(C)CC(O)=O KWIUHFFTVRNATP-UHFFFAOYSA-O 0.000 description 2
- WNLRTRBMVRJNCN-UHFFFAOYSA-N adipic acid Chemical compound OC(=O)CCCCC(O)=O WNLRTRBMVRJNCN-UHFFFAOYSA-N 0.000 description 2
- 229910000147 aluminium phosphate Inorganic materials 0.000 description 2
- 235000010323 ascorbic acid Nutrition 0.000 description 2
- 239000011668 ascorbic acid Substances 0.000 description 2
- 230000009286 beneficial effect Effects 0.000 description 2
- 230000008901 benefit Effects 0.000 description 2
- 229960003237 betaine Drugs 0.000 description 2
- 230000015572 biosynthetic process Effects 0.000 description 2
- 229960003178 choline chloride Drugs 0.000 description 2
- SGMZJAMFUVOLNK-UHFFFAOYSA-M choline chloride Chemical compound [Cl-].C[N+](C)(C)CCO SGMZJAMFUVOLNK-UHFFFAOYSA-M 0.000 description 2
- 229940075419 choline hydroxide Drugs 0.000 description 2
- 239000011248 coating agent Substances 0.000 description 2
- 230000003111 delayed effect Effects 0.000 description 2
- 238000013461 design Methods 0.000 description 2
- 201000010099 disease Diseases 0.000 description 2
- SHEYKHMHFCPWCL-UHFFFAOYSA-N disilanyl-hydroxy-methylsilane Chemical compound C[SiH](O)[SiH2][SiH3] SHEYKHMHFCPWCL-UHFFFAOYSA-N 0.000 description 2
- 208000035475 disorder Diseases 0.000 description 2
- 238000004090 dissolution Methods 0.000 description 2
- 239000002552 dosage form Substances 0.000 description 2
- 238000001035 drying Methods 0.000 description 2
- 238000009505 enteric coating Methods 0.000 description 2
- 239000002702 enteric coating Substances 0.000 description 2
- 210000003238 esophagus Anatomy 0.000 description 2
- 239000012530 fluid Substances 0.000 description 2
- FUZZWVXGSFPDMH-UHFFFAOYSA-N hexanoic acid Chemical compound CCCCCC(O)=O FUZZWVXGSFPDMH-UHFFFAOYSA-N 0.000 description 2
- 230000007062 hydrolysis Effects 0.000 description 2
- 238000006460 hydrolysis reaction Methods 0.000 description 2
- 229910052500 inorganic mineral Inorganic materials 0.000 description 2
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 description 2
- QWDJLDTYWNBUKE-UHFFFAOYSA-L magnesium bicarbonate Chemical compound [Mg+2].OC([O-])=O.OC([O-])=O QWDJLDTYWNBUKE-UHFFFAOYSA-L 0.000 description 2
- 239000002370 magnesium bicarbonate Substances 0.000 description 2
- 229910000022 magnesium bicarbonate Inorganic materials 0.000 description 2
- 235000014824 magnesium bicarbonate Nutrition 0.000 description 2
- GVALZJMUIHGIMD-UHFFFAOYSA-H magnesium phosphate Chemical compound [Mg+2].[Mg+2].[Mg+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O GVALZJMUIHGIMD-UHFFFAOYSA-H 0.000 description 2
- 239000004137 magnesium phosphate Substances 0.000 description 2
- 229960002261 magnesium phosphate Drugs 0.000 description 2
- 229910000157 magnesium phosphate Inorganic materials 0.000 description 2
- 235000010994 magnesium phosphates Nutrition 0.000 description 2
- 229910052943 magnesium sulfate Inorganic materials 0.000 description 2
- 235000019341 magnesium sulphate Nutrition 0.000 description 2
- 239000011707 mineral Substances 0.000 description 2
- 235000010755 mineral Nutrition 0.000 description 2
- 210000000663 muscle cell Anatomy 0.000 description 2
- 239000002858 neurotransmitter agent Substances 0.000 description 2
- 230000000422 nocturnal effect Effects 0.000 description 2
- 238000004806 packaging method and process Methods 0.000 description 2
- SIOXPEMLGUPBBT-UHFFFAOYSA-M picolinate Chemical compound [O-]C(=O)C1=CC=CC=N1 SIOXPEMLGUPBBT-UHFFFAOYSA-M 0.000 description 2
- 229920000642 polymer Polymers 0.000 description 2
- 230000008092 positive effect Effects 0.000 description 2
- 239000000047 product Substances 0.000 description 2
- 238000011321 prophylaxis Methods 0.000 description 2
- 238000012419 revalidation Methods 0.000 description 2
- YGSDEFSMJLZEOE-UHFFFAOYSA-N salicylic acid Chemical compound OC(=O)C1=CC=CC=C1O YGSDEFSMJLZEOE-UHFFFAOYSA-N 0.000 description 2
- 238000007873 sieving Methods 0.000 description 2
- 150000004819 silanols Chemical class 0.000 description 2
- 238000005507 spraying Methods 0.000 description 2
- 210000003699 striated muscle Anatomy 0.000 description 2
- 238000001356 surgical procedure Methods 0.000 description 2
- 230000009182 swimming Effects 0.000 description 2
- 208000024891 symptom Diseases 0.000 description 2
- 230000009897 systematic effect Effects 0.000 description 2
- 210000003371 toe Anatomy 0.000 description 2
- 125000004178 (C1-C4) alkyl group Chemical group 0.000 description 1
- PHIQHXFUZVPYII-ZCFIWIBFSA-O (R)-carnitinium Chemical compound C[N+](C)(C)C[C@H](O)CC(O)=O PHIQHXFUZVPYII-ZCFIWIBFSA-O 0.000 description 1
- IIZPXYDJLKNOIY-JXPKJXOSSA-N 1-palmitoyl-2-arachidonoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCC\C=C/C\C=C/C\C=C/C\C=C/CCCCC IIZPXYDJLKNOIY-JXPKJXOSSA-N 0.000 description 1
- OVSKIKFHRZPJSS-UHFFFAOYSA-N 2,4-D Chemical compound OC(=O)COC1=CC=C(Cl)C=C1Cl OVSKIKFHRZPJSS-UHFFFAOYSA-N 0.000 description 1
- OXJISOJFVQITNG-UHFFFAOYSA-M 2,4-D choline Chemical compound C[N+](C)(C)CCO.[O-]C(=O)COC1=CC=C(Cl)C=C1Cl OXJISOJFVQITNG-UHFFFAOYSA-M 0.000 description 1
- 229940087195 2,4-dichlorophenoxyacetate Drugs 0.000 description 1
- FEDJGPQLLNQAIY-UHFFFAOYSA-N 2-[(6-oxo-1h-pyridazin-3-yl)oxy]acetic acid Chemical compound OC(=O)COC=1C=CC(=O)NN=1 FEDJGPQLLNQAIY-UHFFFAOYSA-N 0.000 description 1
- ZZJFIXMCLZTHQV-UHFFFAOYSA-O 2-carboxyoxyethyl(trimethyl)azanium Chemical compound C[N+](C)(C)CCOC(O)=O ZZJFIXMCLZTHQV-UHFFFAOYSA-O 0.000 description 1
- MIFGTXFTLQVWJW-UHFFFAOYSA-M 2-hydroxyethyl(trimethyl)azanium;2-hydroxypropanoate Chemical compound CC(O)C([O-])=O.C[N+](C)(C)CCO MIFGTXFTLQVWJW-UHFFFAOYSA-M 0.000 description 1
- HYCSHFLKPSMPGO-UHFFFAOYSA-N 3-hydroxypropyl dihydrogen phosphate Chemical compound OCCCOP(O)(O)=O HYCSHFLKPSMPGO-UHFFFAOYSA-N 0.000 description 1
- KZSXRDLXTFEHJM-UHFFFAOYSA-N 5-(trifluoromethyl)benzene-1,3-diamine Chemical compound NC1=CC(N)=CC(C(F)(F)F)=C1 KZSXRDLXTFEHJM-UHFFFAOYSA-N 0.000 description 1
- FHVDTGUDJYJELY-UHFFFAOYSA-N 6-{[2-carboxy-4,5-dihydroxy-6-(phosphanyloxy)oxan-3-yl]oxy}-4,5-dihydroxy-3-phosphanyloxane-2-carboxylic acid Chemical compound O1C(C(O)=O)C(P)C(O)C(O)C1OC1C(C(O)=O)OC(OP)C(O)C1O FHVDTGUDJYJELY-UHFFFAOYSA-N 0.000 description 1
- KPYSYYIEGFHWSV-UHFFFAOYSA-N Baclofen Chemical compound OC(=O)CC(CN)C1=CC=C(Cl)C=C1 KPYSYYIEGFHWSV-UHFFFAOYSA-N 0.000 description 1
- 241000283690 Bos taurus Species 0.000 description 1
- 241000282472 Canis lupus familiaris Species 0.000 description 1
- 108010058699 Choline O-acetyltransferase Proteins 0.000 description 1
- KRKNYBCHXYNGOX-UHFFFAOYSA-K Citrate Chemical compound [O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O KRKNYBCHXYNGOX-UHFFFAOYSA-K 0.000 description 1
- RYGMFSIKBFXOCR-UHFFFAOYSA-N Copper Chemical compound [Cu] RYGMFSIKBFXOCR-UHFFFAOYSA-N 0.000 description 1
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 1
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 1
- RGHNJXZEOKUKBD-SQOUGZDYSA-M D-gluconate Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C([O-])=O RGHNJXZEOKUKBD-SQOUGZDYSA-M 0.000 description 1
- 239000004375 Dextrin Substances 0.000 description 1
- 229920001353 Dextrin Polymers 0.000 description 1
- JYFHYPJRHGVZDY-UHFFFAOYSA-N Dibutyl phosphate Chemical compound CCCCOP(O)(=O)OCCCC JYFHYPJRHGVZDY-UHFFFAOYSA-N 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 241000283086 Equidae Species 0.000 description 1
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 1
- 208000005577 Gastroenteritis Diseases 0.000 description 1
- 206010017999 Gastrointestinal pain Diseases 0.000 description 1
- 239000008777 Glycerylphosphorylcholine Substances 0.000 description 1
- JVTAAEKCZFNVCJ-UHFFFAOYSA-M Lactate Chemical compound CC(O)C([O-])=O JVTAAEKCZFNVCJ-UHFFFAOYSA-M 0.000 description 1
- 241000124008 Mammalia Species 0.000 description 1
- 108010009736 Protein Hydrolysates Proteins 0.000 description 1
- 208000022249 Sleep-Wake Transition disease Diseases 0.000 description 1
- MKRNVBXERAPZOP-UHFFFAOYSA-N Starch acetate Chemical compound O1C(CO)C(OC)C(O)C(O)C1OCC1C(OC2C(C(O)C(OC)C(CO)O2)OC(C)=O)C(O)C(O)C(OC2C(OC(C)C(O)C2O)CO)O1 MKRNVBXERAPZOP-UHFFFAOYSA-N 0.000 description 1
- 239000004355 Starch acetate esterified with vinyl acetate Substances 0.000 description 1
- 241000282887 Suidae Species 0.000 description 1
- 206010044565 Tremor Diseases 0.000 description 1
- 229930003316 Vitamin D Natural products 0.000 description 1
- QYSXJUFSXHHAJI-XFEUOLMDSA-N Vitamin D3 Natural products C1(/[C@@H]2CC[C@@H]([C@]2(CCC1)C)[C@H](C)CCCC(C)C)=C/C=C1\C[C@@H](O)CCC1=C QYSXJUFSXHHAJI-XFEUOLMDSA-N 0.000 description 1
- 239000001361 adipic acid Substances 0.000 description 1
- 235000011037 adipic acid Nutrition 0.000 description 1
- 230000002411 adverse Effects 0.000 description 1
- 229940072056 alginate Drugs 0.000 description 1
- 235000010443 alginic acid Nutrition 0.000 description 1
- 229920000615 alginic acid Polymers 0.000 description 1
- 235000019427 alkaline modified starch Nutrition 0.000 description 1
- AWUCVROLDVIAJX-UHFFFAOYSA-N alpha-glycerophosphate Natural products OCC(O)COP(O)(O)=O AWUCVROLDVIAJX-UHFFFAOYSA-N 0.000 description 1
- XAGFODPZIPBFFR-UHFFFAOYSA-N aluminium Chemical compound [Al] XAGFODPZIPBFFR-UHFFFAOYSA-N 0.000 description 1
- 229910052782 aluminium Inorganic materials 0.000 description 1
- 229940024606 amino acid Drugs 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 229940072107 ascorbate Drugs 0.000 description 1
- 229960005070 ascorbic acid Drugs 0.000 description 1
- 229960000794 baclofen Drugs 0.000 description 1
- 235000013361 beverage Nutrition 0.000 description 1
- 235000019428 bleached starch Nutrition 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 210000000988 bone and bone Anatomy 0.000 description 1
- 210000004556 brain Anatomy 0.000 description 1
- 229960000623 carbamazepine Drugs 0.000 description 1
- FFGPTBGBLSHEPO-UHFFFAOYSA-N carbamazepine Chemical compound C1=CC2=CC=CC=C2N(C(=O)N)C2=CC=CC=C21 FFGPTBGBLSHEPO-UHFFFAOYSA-N 0.000 description 1
- 229960004203 carnitine Drugs 0.000 description 1
- 229940047608 chelated magnesium Drugs 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- SUHOQUVVVLNYQR-MRVPVSSYSA-N choline alfoscerate Chemical compound C[N+](C)(C)CCOP([O-])(=O)OC[C@H](O)CO SUHOQUVVVLNYQR-MRVPVSSYSA-N 0.000 description 1
- 229940001468 citrate Drugs 0.000 description 1
- 238000002648 combination therapy Methods 0.000 description 1
- 230000000052 comparative effect Effects 0.000 description 1
- 235000009508 confectionery Nutrition 0.000 description 1
- 210000002808 connective tissue Anatomy 0.000 description 1
- 239000010949 copper Substances 0.000 description 1
- 229910052802 copper Inorganic materials 0.000 description 1
- 230000001351 cycling effect Effects 0.000 description 1
- 235000019425 dextrin Nutrition 0.000 description 1
- 238000000502 dialysis Methods 0.000 description 1
- IRDLUHRVLVEUHA-UHFFFAOYSA-N diethyl dithiophosphate Chemical compound CCOP(S)(=S)OCC IRDLUHRVLVEUHA-UHFFFAOYSA-N 0.000 description 1
- SSAJNPNVUYMUCI-UHFFFAOYSA-N diethyl-[2-[2-(naphthalen-1-ylmethyl)-3-(oxolan-2-yl)propanoyl]oxyethyl]azanium;2-hydroxy-2-oxoacetate Chemical compound OC(=O)C([O-])=O.C=1C=CC2=CC=CC=C2C=1CC(C(=O)OCC[NH+](CC)CC)CC1CCCO1 SSAJNPNVUYMUCI-UHFFFAOYSA-N 0.000 description 1
- 230000029087 digestion Effects 0.000 description 1
- 229960005316 diltiazem hydrochloride Drugs 0.000 description 1
- 239000006185 dispersion Substances 0.000 description 1
- 235000013804 distarch phosphate Nutrition 0.000 description 1
- 230000035622 drinking Effects 0.000 description 1
- 239000006196 drop Substances 0.000 description 1
- 230000000792 effect on seizure Effects 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 238000001125 extrusion Methods 0.000 description 1
- 239000007888 film coating Substances 0.000 description 1
- 238000009501 film coating Methods 0.000 description 1
- 239000000796 flavoring agent Substances 0.000 description 1
- 235000019634 flavors Nutrition 0.000 description 1
- 238000005243 fluidization Methods 0.000 description 1
- 235000011389 fruit/vegetable juice Nutrition 0.000 description 1
- 229960002870 gabapentin Drugs 0.000 description 1
- 229940050410 gluconate Drugs 0.000 description 1
- 229960004956 glycerylphosphorylcholine Drugs 0.000 description 1
- 230000036449 good health Effects 0.000 description 1
- 229940093915 gynecological organic acid Drugs 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- RLMXGBGAZRVYIX-UHFFFAOYSA-N hexane-1,2,3,6-tetrol Chemical compound OCCCC(O)C(O)CO RLMXGBGAZRVYIX-UHFFFAOYSA-N 0.000 description 1
- 238000007757 hot melt coating Methods 0.000 description 1
- LPPJNZJBKFSQGA-UHFFFAOYSA-M hydron;2-hydroxyethyl(trimethyl)azanium;phosphate Chemical compound OP(O)([O-])=O.C[N+](C)(C)CCO LPPJNZJBKFSQGA-UHFFFAOYSA-M 0.000 description 1
- 239000001341 hydroxy propyl starch Substances 0.000 description 1
- 235000013828 hydroxypropyl starch Nutrition 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 210000000876 intercostal muscle Anatomy 0.000 description 1
- 210000000936 intestine Anatomy 0.000 description 1
- 208000017169 kidney disease Diseases 0.000 description 1
- 229940001447 lactate Drugs 0.000 description 1
- 239000004310 lactic acid Substances 0.000 description 1
- 235000014655 lactic acid Nutrition 0.000 description 1
- 239000000787 lecithin Substances 0.000 description 1
- 235000010445 lecithin Nutrition 0.000 description 1
- 229940067606 lecithin Drugs 0.000 description 1
- 210000002414 leg Anatomy 0.000 description 1
- 229910001629 magnesium chloride Inorganic materials 0.000 description 1
- 229960002337 magnesium chloride Drugs 0.000 description 1
- 235000011147 magnesium chloride Nutrition 0.000 description 1
- 239000001755 magnesium gluconate Substances 0.000 description 1
- 229960003035 magnesium gluconate Drugs 0.000 description 1
- 235000015778 magnesium gluconate Nutrition 0.000 description 1
- OVGXLJDWSLQDRT-UHFFFAOYSA-L magnesium lactate Chemical compound [Mg+2].CC(O)C([O-])=O.CC(O)C([O-])=O OVGXLJDWSLQDRT-UHFFFAOYSA-L 0.000 description 1
- 239000000626 magnesium lactate Substances 0.000 description 1
- 229960004658 magnesium lactate Drugs 0.000 description 1
- 235000015229 magnesium lactate Nutrition 0.000 description 1
- 239000000395 magnesium oxide Substances 0.000 description 1
- CPLXHLVBOLITMK-UHFFFAOYSA-N magnesium oxide Inorganic materials [Mg]=O CPLXHLVBOLITMK-UHFFFAOYSA-N 0.000 description 1
- 229960000869 magnesium oxide Drugs 0.000 description 1
- 235000012245 magnesium oxide Nutrition 0.000 description 1
- 229960003390 magnesium sulfate Drugs 0.000 description 1
- IAKLPCRFBAZVRW-XRDLMGPZSA-L magnesium;(2r,3s,4r,5r)-2,3,4,5,6-pentahydroxyhexanoate;hydrate Chemical compound O.[Mg+2].OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C([O-])=O.OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C([O-])=O IAKLPCRFBAZVRW-XRDLMGPZSA-L 0.000 description 1
- QYOBXHXZJRPWDE-JIZZDEOASA-L magnesium;(2s)-2-amino-4-hydroxy-4-oxobutanoate;chloride Chemical compound [Mg+2].Cl.[O-]C(=O)[C@@H](N)CC([O-])=O QYOBXHXZJRPWDE-JIZZDEOASA-L 0.000 description 1
- AXZKOIWUVFPNLO-UHFFFAOYSA-N magnesium;oxygen(2-) Chemical compound [O-2].[Mg+2] AXZKOIWUVFPNLO-UHFFFAOYSA-N 0.000 description 1
- 230000014759 maintenance of location Effects 0.000 description 1
- 229940049920 malate Drugs 0.000 description 1
- BJEPYKJPYRNKOW-UHFFFAOYSA-N malic acid Chemical compound OC(=O)C(O)CC(O)=O BJEPYKJPYRNKOW-UHFFFAOYSA-N 0.000 description 1
- 238000007726 management method Methods 0.000 description 1
- 238000002483 medication Methods 0.000 description 1
- 230000005906 menstruation Effects 0.000 description 1
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 1
- 235000013336 milk Nutrition 0.000 description 1
- 239000008267 milk Substances 0.000 description 1
- 210000004080 milk Anatomy 0.000 description 1
- 235000013807 monostarch phosphate Nutrition 0.000 description 1
- 239000001248 monostarch phosphate Substances 0.000 description 1
- 230000000877 morphologic effect Effects 0.000 description 1
- 210000004165 myocardium Anatomy 0.000 description 1
- 229960001132 naftidrofuryl Drugs 0.000 description 1
- 210000001640 nerve ending Anatomy 0.000 description 1
- 210000000715 neuromuscular junction Anatomy 0.000 description 1
- 201000001119 neuropathy Diseases 0.000 description 1
- 230000007823 neuropathy Effects 0.000 description 1
- 235000015097 nutrients Nutrition 0.000 description 1
- 235000005985 organic acids Nutrition 0.000 description 1
- 229960001816 oxcarbazepine Drugs 0.000 description 1
- CTRLABGOLIVAIY-UHFFFAOYSA-N oxcarbazepine Chemical compound C1C(=O)C2=CC=CC=C2N(C(=O)N)C2=CC=CC=C21 CTRLABGOLIVAIY-UHFFFAOYSA-N 0.000 description 1
- 230000003647 oxidation Effects 0.000 description 1
- 238000007254 oxidation reaction Methods 0.000 description 1
- 235000013808 oxidized starch Nutrition 0.000 description 1
- FJKROLUGYXJWQN-UHFFFAOYSA-N papa-hydroxy-benzoic acid Natural products OC(=O)C1=CC=C(O)C=C1 FJKROLUGYXJWQN-UHFFFAOYSA-N 0.000 description 1
- 239000004031 partial agonist Substances 0.000 description 1
- 210000003903 pelvic floor Anatomy 0.000 description 1
- 208000033808 peripheral neuropathy Diseases 0.000 description 1
- 239000000825 pharmaceutical preparation Substances 0.000 description 1
- 229940127557 pharmaceutical product Drugs 0.000 description 1
- WTJKGGKOPKCXLL-RRHRGVEJSA-N phosphatidylcholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCCCCCCC=CCCCCCCCC WTJKGGKOPKCXLL-RRHRGVEJSA-N 0.000 description 1
- YHHSONZFOIEMCP-UHFFFAOYSA-O phosphocholine Chemical compound C[N+](C)(C)CCOP(O)(O)=O YHHSONZFOIEMCP-UHFFFAOYSA-O 0.000 description 1
- 150000003016 phosphoric acids Chemical class 0.000 description 1
- 229950004354 phosphorylcholine Drugs 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 230000035935 pregnancy Effects 0.000 description 1
- 102000004196 processed proteins & peptides Human genes 0.000 description 1
- ZHNFLHYOFXQIOW-LPYZJUEESA-N quinine sulfate dihydrate Chemical compound [H+].[H+].O.O.[O-]S([O-])(=O)=O.C([C@H]([C@H](C1)C=C)C2)C[N@@]1[C@@H]2[C@H](O)C1=CC=NC2=CC=C(OC)C=C21.C([C@H]([C@H](C1)C=C)C2)C[N@@]1[C@@H]2[C@H](O)C1=CC=NC2=CC=C(OC)C=C21 ZHNFLHYOFXQIOW-LPYZJUEESA-N 0.000 description 1
- 238000011084 recovery Methods 0.000 description 1
- 229960004889 salicylic acid Drugs 0.000 description 1
- 238000005029 sieve analysis Methods 0.000 description 1
- 150000004760 silicates Chemical class 0.000 description 1
- 239000002210 silicon-based material Substances 0.000 description 1
- 238000009097 single-agent therapy Methods 0.000 description 1
- 208000024450 sleep related movement disease Diseases 0.000 description 1
- 239000000779 smoke Substances 0.000 description 1
- 230000016160 smooth muscle contraction Effects 0.000 description 1
- AWUCVROLDVIAJX-GSVOUGTGSA-N sn-glycerol 3-phosphate Chemical compound OC[C@@H](O)COP(O)(O)=O AWUCVROLDVIAJX-GSVOUGTGSA-N 0.000 description 1
- 159000000000 sodium salts Chemical class 0.000 description 1
- UGTZMIPZNRIWHX-UHFFFAOYSA-K sodium trimetaphosphate Chemical compound [Na+].[Na+].[Na+].[O-]P1(=O)OP([O-])(=O)OP([O-])(=O)O1 UGTZMIPZNRIWHX-UHFFFAOYSA-K 0.000 description 1
- XDLYMKFUPYZCMA-UHFFFAOYSA-M sodium;4-oct-1-enoxy-4-oxobutanoate Chemical compound [Na+].CCCCCCC=COC(=O)CCC([O-])=O XDLYMKFUPYZCMA-UHFFFAOYSA-M 0.000 description 1
- 239000000600 sorbitol Substances 0.000 description 1
- 235000011496 sports drink Nutrition 0.000 description 1
- 230000006641 stabilisation Effects 0.000 description 1
- 238000011105 stabilization Methods 0.000 description 1
- 235000019430 starch acetate esterified with vinyl acetate Nutrition 0.000 description 1
- 210000002784 stomach Anatomy 0.000 description 1
- 239000013589 supplement Substances 0.000 description 1
- 230000009469 supplementation Effects 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 230000002195 synergetic effect Effects 0.000 description 1
- 235000020357 syrup Nutrition 0.000 description 1
- 239000006188 syrup Substances 0.000 description 1
- 229940104261 taurate Drugs 0.000 description 1
- 229960003080 taurine Drugs 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 239000011573 trace mineral Substances 0.000 description 1
- 235000013619 trace mineral Nutrition 0.000 description 1
- 238000012546 transfer Methods 0.000 description 1
- 238000009827 uniform distribution Methods 0.000 description 1
- 210000003708 urethra Anatomy 0.000 description 1
- 235000012141 vanillin Nutrition 0.000 description 1
- MWOOGOJBHIARFG-UHFFFAOYSA-N vanillin Chemical compound COC1=CC(C=O)=CC=C1O MWOOGOJBHIARFG-UHFFFAOYSA-N 0.000 description 1
- FGQOOHJZONJGDT-UHFFFAOYSA-N vanillin Natural products COC1=CC(O)=CC(C=O)=C1 FGQOOHJZONJGDT-UHFFFAOYSA-N 0.000 description 1
- 235000019158 vitamin B6 Nutrition 0.000 description 1
- 239000011726 vitamin B6 Substances 0.000 description 1
- 235000019166 vitamin D Nutrition 0.000 description 1
- 239000011710 vitamin D Substances 0.000 description 1
- 150000003710 vitamin D derivatives Chemical class 0.000 description 1
- 229940046008 vitamin d Drugs 0.000 description 1
- 239000004554 water soluble tablet Substances 0.000 description 1
- 238000005550 wet granulation Methods 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
- A61K33/06—Aluminium, calcium or magnesium; Compounds thereof, e.g. clay
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/695—Silicon compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/74—Synthetic polymeric materials
- A61K31/80—Polymers containing hetero atoms not provided for in groups A61K31/755 - A61K31/795
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
- A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
- A61K47/186—Quaternary ammonium compounds, e.g. benzalkonium chloride or cetrimide
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A61P21/02—Muscle relaxants, e.g. for tetanus or cramps
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Epidemiology (AREA)
- Inorganic Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Physical Education & Sports Medicine (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Neurology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pain & Pain Management (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Nutrition Science (AREA)
- Physiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
Abstract
Description
本発明はさらに、医薬の投与による筋痙攣の予防、抑制、及び治療の方法に関する。
したがって、本発明の目的は、筋痙攣の予防、抑制、又は治療に使用するための医薬を提供することである。
79歳の男性患者は23年のあいだ再発性の筋痙攣を有していた。筋痙攣は、手、下腕、脚の骨格筋、並びに肋間筋において発生した。それ以外の点では、患者は健康であり、他の薬を服用せず、喫煙もせず、常習的にコーヒーとアルコールを摂取しているもののそれらに対する中毒になることはなかった。筋痙攣は、1日当たり数回の痙攣の頻度で日中及び夜間に発生した。その結果、筋痙攣は、医者として働くことを阻害し、さらに水泳やその他のスポーツをできなくした。その患者は、1日当たり450mgの毎日の投与でマグネシウム(塩として)の治療を受けていたが、これは有効ではなく、筋痙攣の緩和又は抑制をもたらさなかった。この有効でないという結果は、マグネシウムの補給は筋痙攣の治療に有効ではないというGarrison(上記)及ぶYoung(上記)の結論と整合している。
例1の患者は、生物学的に利用可能なケイ素とマグネシウムの組み合わせ物を、前記の1日用量で1年間治療を継続した。彼は痙攣がないままだった。
59歳の人が、2本の足指の位置をまっすぐにし、他の2本の足指を短くするための足の手術を受けた。手術後の再検証中に、手術した足に筋痙攣がその人に発生した。筋痙攣は、毎日、一日のあいだ、そして足が疲れているときにはるかに多く発生した。さらに、特定の足の位置、例えば、靴下や靴を履くために必要な足の位置が、筋痙攣を引き起こした。
80歳の人が、数年の間、夜間性の筋痙攣を起こし、重大な睡眠障害及びそれに関連する倦怠感を引き起こしていた。彼は、固体形態のBiosil(登録商標)として生物学的に利用可能なケイ素、及びPromagnor(商標)としてマグネシウムを投与された。1日用量は10mgのケイ素(元素質量)及び450mgのマグネシウム(元素質量)だった。コリン安定剤はそれらとともに200mgの1日用量で投与された。痙攣は完全に消失した。
看護師として雇われた52歳の人が、昼と夜に何回かの筋痙攣に直面した。さらに、その人は関節に問題があった。彼女は、固体形態のBiosil(登録商標)として生物学的に利用可能なケイ素及びとPromagnor(商標)の形態でマグネシウムを投与された。1日用量は10mgのケイ素(元素質量)及び450mgのマグネシウム(元素質量)だった。コリン安定剤はそれらとともに200mgの1日用量で投与された。その人は10日間の治療後に痙攣がなくなった。関節の痛みも消えた。
看護師である43歳の人がランニング(スポーツ)中に痙攣を起こした。痙攣は約2km走った後に始まった。痙攣はスポーツ中にのみ発生し、したがって偶発的である。彼女は、固体形態のBiosil(登録商標)として生物学的に利用可能なケイ素を投与され、Promagnor(商標)の形態でマグネシウムが投与された。1日用量は10mgのケイ素(元素質量)と450mgのマグネシウム(元素質量)だった。コリン安定剤はそれらとともに200mgの1日用量で投与された。ランニング中の偶発的な痙攣が再び起こることはなかった。
ジャーナリストとして雇われた75歳の人は腎臓病患者で、週に3回、4時間の透析を受けていた。筋痙攣は、日中、少なくとも週に1~2回、特に手で発生し、これにより書くのが面倒になっていた。彼は、固体形態のBiosil(登録商標)として生物学的に利用可能なケイ素を、そしてPromagnor(商標)の形態でマグネシウムを投与された。1日用量は10mgのケイ素(元素質量)及び450mgのマグネシウム(元素質量)だった。コリン安定剤はそれらとともに200mgの1日用量で投与された。痙攣は消失した。
頻繁な筋痙攣を経験している女性と男性の患者(33歳から86歳)がクロスオーバー試験に参加した。クロスオーバー試験の設計は次のとおりである。
期間1:2週間の経口400mgのMg/日(クエン酸マグネシウム)、
期間2:2週間の経口400mgのMg/日+10mgのSi/日(クエン酸マグネシウム及びコリンで安定化されたオルトケイ酸)、
期間3:2週間の経口200mgのMg/日+5mgのSi/日(クエン酸マグネシウム及びコリンで安定化されたオルトケイ酸)。
パラメータ:患者は日記に毎日の痙攣の頻度を記録した。
頻繁な筋痙攣を経験している7人の女性及び4人の男性の患者(27~86歳、平均年齢56歳)が、次のデザインの比較試験に参加した。
期間1:1週間の間に11人の患者が、
(a)経口マグネシウムサプリメント(6人の患者)を継続した、又は
(b)経口マグネシウム治療(2人の患者)から180mgのMg/日(リンゴ酸マグネシウム)の経口マグネシウムサプリメントに変更した、又は
(c)「マグネシウムなし」の前治療(3人の患者)から180mgのMg/日の経口マグネシウムサプリメント(リンゴ酸マグネシウム)に変更した。
1人の患者は期間1の前に硫酸キニーネを服用していた。
期間2:すべての患者(n=11)は、4週間の360mgのMg/日(リンゴ酸マグネシウム)+10mgのSi/日(コリン安定化オルトケイ酸、ch-OSA(登録商標))。
パラメータ:患者は日記に痙攣の頻度を毎日記録した。
結果は次のとおりである。
Claims (15)
- 筋痙攣の予防、抑制、又は治療に使用するための、薬学的に有効な量の生物学的に利用可能なケイ素、及び薬学的に有効な量の生物学的に利用可能なマグネシウム化合物を含む医薬組成物。
- 生物学的に利用可能なケイ素と生物学的に利用可能なマグネシウムの組み合わせが、再発性及び/又は特発性の筋痙攣の予防、抑制、又は治療に使用するためのものである、請求項1に記載の医薬組成物。
- 筋痙攣が骨格筋痙攣及び/又は平滑筋痙攣を含む、請求項1又は2に記載の医薬組成物。
- 骨格筋の痙攣が、四肢、例えば、脚、足、及び手の痙攣である、請求項3に記載の医薬組成物。
- 平滑筋痙攣が、消化管平滑筋、例えば、食道、胃、及び腸の平滑筋の痙攣、又は子宮頸部平滑筋の痙攣である、請求項3に記載の医薬組成物。
- ケイ素及びマグネシウムが、経口で又は非経口で、同時に、別々に、又は時間をずらして投与される、請求項1~5のいずれか一項に記載の医薬組成物。
- ケイ素及びマグネシウムが毎日投与される、請求項1~6のいずれか一項に記載の医薬組成物。
- 生物学的に利用可能なケイ素の薬学的に有効な量が、一用量で、少なくとも3mg/日のケイ素元素、好ましくは少なくとも5mg/日、より好ましくは少なくとも8mg/日の用量であり、かつ、マグネシウム化合物の薬学的に有効な量が、一用量で、50~600mg/日のマグネシウム元素、好ましくは一用量につき、100~500mg/日である、請求項1~7のいずれか一項に記載の医薬組成物。
- 少なくとも3mg、好ましくは少なくとも5mg、より好ましくは少なくとも8mgのケイ素元素の1日用量に相当する薬学的に有効な量の生物学的に利用可能なケイ素、及び
50~500mgのマグネシウム元素の一日用量、好ましくは100~450mg、例えば、200~400mgのマグネシウム元素の一日用量に相当する薬学的に有効な量のマグネシウム化合物を含む医薬組成物。 - 医薬組成物が別個の剤形の医薬の組み合わせ物であるか、又は生物学的に利用可能なケイ素及び生物学的に利用可能なマグネシウム化合物が単一の製剤の一部である、請求項1~9のいずれか一項に記載の医薬組成物。
- 生物学的に利用可能なケイ素が、式YxSi(OH)4-xのケイ素化合物又はそのオリゴマーであり、式中、Yは任意選択で置換されていてもよい(C1~C4)アルキル、(C2~C5)アルケニル、(C1~C4)アルコキシ、アミノであり、かつ、xは0~2であり、好ましくは、ケイ素化合物はオルトケイ酸又はそのオリゴマー(式中、x=0)及びモノ(C1~C4)アルキルトリシラノール、及びそれらの組み合わせから選択され、さらに好ましくは、ケイ素化合物はオルトケイ酸又はそのオリゴマーである、請求項1~10のいずれか一項に記載の医薬組成物。
- ケイ素化合物が、そのケイ素化合物の重合を阻害する安定化剤とともに提供され、前記安定化剤が、好ましくは、アミノ酸、ペプチド、及びタンパク質加水分解物、有機酸、フェノール及びポリフェノール化合物、多価アルコール、例えばマルトデキストリン、第四級アンモニウム化合物及びアルデヒドの群から選択され、好ましくは、安定化剤が第四級アンモニウム化合物であるか又は第四級アンモニウム化合物を含み、最も好ましくは安定化剤がコリンである、請求項11に記載の医薬組成物。
- マグネシウムが、マグネシウム塩、例えば、無機マグネシウム塩及び/又は有機マグネシウム塩、好ましくは有機マグネシウム塩、より好ましくは少なくとも2つの有機マグネシウム塩として経口投与のために提供される、請求項1~12のいずれか一項に記載の医薬組成物。
- ケイ素化合物がさらに結合剤材料とともに提供され、ケイ素化合物、安定化剤、及び結合剤の組み合わせ物が顆粒形態であり、ここで、マグネシウムが固体形態であり、前記顆粒及びマグネシウムが固形混合物として医薬製剤中に存在する、請求項1~13のいずれか一項に記載の医薬組成物。
- 結合剤が水溶性結合剤材料、例えば冷水可溶性デンプンである、請求項14に記載の医薬組成物。
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP19157526.5 | 2019-02-15 | ||
EP19157526.5A EP3695843A1 (en) | 2019-02-15 | 2019-02-15 | Medicament for the prevention and treatment of muscle cramps |
PCT/EP2020/053912 WO2020165415A1 (en) | 2019-02-15 | 2020-02-14 | Combination of silicon and magnesium for the prevention and treatment of muscle cramps |
Publications (2)
Publication Number | Publication Date |
---|---|
JP2022520962A true JP2022520962A (ja) | 2022-04-04 |
JP7507772B2 JP7507772B2 (ja) | 2024-06-28 |
Family
ID=65443783
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2021547506A Active JP7507772B2 (ja) | 2019-02-15 | 2020-02-14 | 筋痙攣の予防及び治療のためのケイ素及びマグネシウムの組合せ物 |
Country Status (11)
Country | Link |
---|---|
US (1) | US20220143078A1 (ja) |
EP (2) | EP3695843A1 (ja) |
JP (1) | JP7507772B2 (ja) |
KR (1) | KR20220004956A (ja) |
CN (1) | CN113853202A (ja) |
AU (1) | AU2020223517A1 (ja) |
BR (1) | BR112021015682A2 (ja) |
CA (1) | CA3129115A1 (ja) |
EA (1) | EA202192257A1 (ja) |
IL (1) | IL285491A (ja) |
WO (1) | WO2020165415A1 (ja) |
Families Citing this family (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
IT202200009089A1 (it) | 2022-05-04 | 2023-11-04 | Geofarma S R L | Composizione a base di silicio biodisponibile e vitamine |
Family Cites Families (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5922765A (en) * | 1996-01-18 | 1999-07-13 | Fleming & Company, Pharmaceuticals | Methods and compositions for the prevention and treatment of muscle cramps and improving muscular strength |
US20050196434A1 (en) * | 2004-03-04 | 2005-09-08 | Brierre Barbara T. | Pharmaceutical composition and method for the transdermal delivery of magnesium |
US20050220865A1 (en) * | 2004-04-02 | 2005-10-06 | Koleng John J | Compressed composition comprising magnesium salt |
US20100323016A1 (en) | 2008-07-18 | 2010-12-23 | Biljana Nadjsombati | Modified release formulation and methods of use |
WO2010102071A1 (en) | 2009-03-03 | 2010-09-10 | Xenoport, Inc. | Sustained release oral dosage forms of an r-baclofen prodrug |
WO2012035364A1 (en) * | 2010-09-15 | 2012-03-22 | Creogen D.O.O. | Stabilized solution of ortho-silicic acid, its preparation and use |
US20140018750A1 (en) | 2012-07-10 | 2014-01-16 | Michael J. Pagliaro | Method and device or pharmaceutical compositions for the transdermal delivery of magnesium directly to the neuromuscular junction for the treatment of muscle cramping |
EP3307083A4 (en) * | 2015-06-11 | 2019-05-22 | Beachbody, LLC | COMPOSITIONS AND METHODS FOR IMPROVING TRAINING PERFORMANCE AND RECREATION |
JP6771274B2 (ja) * | 2015-08-07 | 2020-10-21 | ロート製薬株式会社 | 内服用組成物 |
-
2019
- 2019-02-15 EP EP19157526.5A patent/EP3695843A1/en not_active Withdrawn
-
2020
- 2020-02-14 KR KR1020217029811A patent/KR20220004956A/ko unknown
- 2020-02-14 EA EA202192257A patent/EA202192257A1/ru unknown
- 2020-02-14 BR BR112021015682-8A patent/BR112021015682A2/pt unknown
- 2020-02-14 US US17/430,931 patent/US20220143078A1/en active Pending
- 2020-02-14 CA CA3129115A patent/CA3129115A1/en active Pending
- 2020-02-14 AU AU2020223517A patent/AU2020223517A1/en active Pending
- 2020-02-14 JP JP2021547506A patent/JP7507772B2/ja active Active
- 2020-02-14 CN CN202080029394.7A patent/CN113853202A/zh active Pending
- 2020-02-14 EP EP20704876.0A patent/EP3923955A1/en active Pending
- 2020-02-14 WO PCT/EP2020/053912 patent/WO2020165415A1/en unknown
-
2021
- 2021-08-10 IL IL285491A patent/IL285491A/en unknown
Also Published As
Publication number | Publication date |
---|---|
KR20220004956A (ko) | 2022-01-12 |
CN113853202A (zh) | 2021-12-28 |
JP7507772B2 (ja) | 2024-06-28 |
BR112021015682A2 (pt) | 2021-10-26 |
CA3129115A1 (en) | 2020-08-20 |
EP3695843A1 (en) | 2020-08-19 |
WO2020165415A1 (en) | 2020-08-20 |
IL285491A (en) | 2021-09-30 |
AU2020223517A1 (en) | 2021-08-19 |
EP3923955A1 (en) | 2021-12-22 |
EA202192257A1 (ru) | 2021-11-01 |
US20220143078A1 (en) | 2022-05-12 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US20230240984A1 (en) | Dimethyl sulfoxide (dmso) and methylsulfonylmethane (msm) formulations to treat osteoarthritis | |
US20050196434A1 (en) | Pharmaceutical composition and method for the transdermal delivery of magnesium | |
US8536199B2 (en) | Oral combination of vitamins | |
JP7206223B2 (ja) | パーキンソン病の予防および/または支持治療処置のための物質 | |
CA3211891A1 (en) | Paraxanthine-based compositions for promoting weight loss | |
CN113811293A (zh) | 包裹在微珠中的酮体 | |
JP2011512392A (ja) | 医薬 | |
JP7507772B2 (ja) | 筋痙攣の予防及び治療のためのケイ素及びマグネシウムの組合せ物 | |
US20110117070A1 (en) | Compositions and methods for treating headache | |
US10610556B2 (en) | Compositions for regulation and control of appetite | |
EA044977B1 (ru) | Комбинация кремния и магния для предупреждения и лечения мышечных судорог | |
JP6625986B2 (ja) | カカオポリフェノール及び好酸球性食道炎の治療又は予防におけるその使用 | |
WO2017186954A1 (en) | Method for the improvement of speed and endurance capacity | |
JP7372269B2 (ja) | α-ラクトアルブミンに基づく医薬品または食品サプリメントの調製物 | |
CA2969334A1 (en) | Use of 2-methylene-19-nor-(20s)-1a,25-dihydroxyvitamin d3 to treat secondary hyperparathyroidism | |
US11364218B2 (en) | Method of treating or preventing mood disorders, mental disorders, and/or chronic fatigue syndrome | |
US9308261B2 (en) | Compositions and methods for treating varicose veins | |
JP2011068614A (ja) | ビタミン製剤 | |
JP2022540664A (ja) | 石灰化減少に用いる経口ピロリン酸二ナトリウム | |
FR3103702A1 (fr) | Utilisation de NMN pour la prévention et/ou le traitement de la spondylarthrite ankylosante et compositions correspondantes | |
JP2018500373A (ja) | 原発性副甲状腺機能亢進症を処置するための2−メチレン−19−ノル−(20S)−1α,25−ジヒドロキシビタミンD3の使用 | |
US20090047334A1 (en) | Transdermal patch for extended delivery of calcium | |
AU2015202432A1 (en) | Dimethyl sulfoxide (DMSO) and methylsulfonylmethane (MSM) formulations to treat osteoarthritis | |
MX2013002803A (es) | Composicion farmaceutica con unidades flotantes de liberacion modificada y unidades de liberacion inmediata o modificada. | |
JPH09136833A (ja) | 疲労回復のための組成物 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20230118 |
|
A977 | Report on retrieval |
Free format text: JAPANESE INTERMEDIATE CODE: A971007 Effective date: 20231219 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20240109 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20240401 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A821 Effective date: 20240402 |
|
TRDD | Decision of grant or rejection written | ||
A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20240520 |
|
A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20240618 |